Skip to content

Study · Animal study (in vivo) · minipig, monkey and rat · 2020

15 results

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Hargrove DM, Alagarsamy S, Croston G, Laporte R, Qi S, Srinivasan K, Sueiras-Diaz J, Wiśniewski K, Hartwig J, Lu M, Posch AP, Wiśniewska H, Schteingart CD, Rivière PJ, Dimitriadou V

The Journal of pharmacology and experimental therapeutics19 Feb 2020Cited by 51 (Europe PMC)

PMID32075870 (opens in a new tab)DOI10.1124/jpet.119.262238 (opens in a new tab)PepBankPUB-32075870
Source linkPubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rat pharmacokinetic studies, apraglutide had lower clearance than teduglutide and glepaglutide.

    In plain wordsIn rats, apraglutide had lower clearance than teduglutide and glepaglutide.

    Peptide
    Apraglutide
    Outcome
    DecreaseClearance
    Study

    ratn: not reported in source

    Comparator
    teduglutide and glepaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacokinetic (PK) and pharmacodynamic studies confirm that apraglutide, a novel GLP-2 analog, has very low clearance, long elimination half-life, and high plasma protein binding compared with GLP-2 analogs teduglutide and glepaglutide.
    1 context sentence
    Summary · context
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rat pharmacokinetic studies, apraglutide had a longer elimination half-life than teduglutide and glepaglutide.

    In plain wordsIn rats, apraglutide had a longer half-life than teduglutide and glepaglutide.

    Peptide
    Apraglutide
    Outcome
    IncreaseElimination half-life
    Study

    ratn: not reported in source

    Comparator
    teduglutide and glepaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacokinetic (PK) and pharmacodynamic studies confirm that apraglutide, a novel GLP-2 analog, has very low clearance, long elimination half-life, and high plasma protein binding compared with GLP-2 analogs teduglutide and glepaglutide.
    1 context sentence
    Summary · context
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, intravenous apraglutide clearance was 0.27 ml/kg per minute.

    In plain wordsIn rats, intravenous apraglutide clearance was 0.27 ml/kg per minute.

    Peptide
    Apraglutide
    Outcome
    Not applicableClearance in rats
    Study

    ratn: not reported in source

    intravenous PK studies
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Clearance
    0.27 ml/kg per minute
    apraglutide

    Source sentences

    Summary
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, intravenous apraglutide had an elimination half-life of 159 minutes.

    In plain wordsIn rats, intravenous apraglutide had a half-life of 159 minutes.

    Peptide
    Apraglutide
    Outcome
    Not applicableElimination half-life in rats
    Study

    ratn: not reported in source

    intravenous PK studies
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Elimination half-life
    159 minutes
    apraglutide

    Source sentences

    Summary
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In monkeys, intravenous and subcutaneous studies confirmed apraglutide's distinctive PK profile.

    In plain wordsIn monkeys, intravenous and under-skin dosing confirmed apraglutide's distinctive drug exposure profile.

    Peptide
    Apraglutide
    Outcome
    Not applicablePK profile in monkeys
    Study

    monkeyn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous and subcutaneousAs given in this study (monkey).

    Source sentences

    Summary
    The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In minipigs, intravenous and subcutaneous studies confirmed apraglutide's distinctive PK profile.

    In plain wordsIn minipigs, intravenous and under-skin dosing confirmed apraglutide's distinctive drug exposure profile.

    Peptide
    Apraglutide
    Outcome
    Not applicablePK profile in minipigs
    Study

    minipign: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous and subcutaneousAs given in this study (minipig).

    Source sentences

    Summary
    The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats, apraglutide showed greater small-intestinal growth activity, including at less-frequent dosing than other peptides.

    In plain wordsIn rats, apraglutide promoted more small-intestinal growth than other peptides at less-frequent dosing.

    Peptide
    Apraglutide
    Outcome
    IncreaseSmall-intestinal growth
    Study

    ratn: not reported in source

    Comparator
    other GLP-2 peptides
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats.
    1 context sentence
    Summary · context
    Apraglutide showed greater intestinotrophic activity than the other peptides when administered at less-frequent dosing intervals because of its prolonged half-life.
  8. 08AnimalAnimal study (in vivo)Pharmacokinetics

    In rats receiving intravenous teduglutide, clearance was 9.9 ml/kg per minute.

    In plain wordsIn rats, intravenous teduglutide clearance was 9.9 ml/kg per minute.

    Peptide
    Teduglutide
    Outcome
    Not applicableClearance
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Clearance
    9.9 ml/kg per minute
    Intravenous teduglutide

    Source sentences

    Summary
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  9. 09AnimalAnimal study (in vivo)Pharmacokinetics

    In rats receiving intravenous teduglutide, elimination half-life was 19 minutes.

    In plain wordsIn rats, intravenous teduglutide had an elimination half-life of 19 minutes.

    Peptide
    Teduglutide
    Outcome
    Not applicableElimination half-life
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Elimination half-life
    19 minutes
    Intravenous teduglutide

    Source sentences

    Summary
    In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats at less-frequent dosing intervals, teduglutide had lower intestinotrophic activity than apraglutide.

    In plain wordsIn rats at less-frequent dosing intervals, teduglutide promoted less intestinal growth than apraglutide.

    Peptide
    Teduglutide
    Outcome
    DecreaseIntestinotrophic activity at less-frequent dosing
    Study

    ratn: not reported in source

    Comparator
    Apraglutide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apraglutide showed greater intestinotrophic activity than the other peptides when administered at less-frequent dosing intervals because of its prolonged half-life.
    1 context sentence
    Summary · context
    The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats.
  11. 11LabIn vitro (cells)Activity measurement

    In receptor studies, apraglutide retained GLP-2 receptor potency comparable to native hGLP-2.

    In plain wordsIn lab tests, apraglutide had GLP-2 receptor potency comparable to native hGLP-2.

    Peptide
    Apraglutide
    Outcome
    No significant changeGLP-2 receptor potency
    Study

    n: not reported in source

    GLP-2 receptor assay
    Comparator
    native hGLP-2
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective.
  12. 12LabIn vitro (cells)Activity measurement

    In receptor studies, apraglutide retained GLP-2 receptor selectivity comparable to native hGLP-2.

    In plain wordsIn lab tests, apraglutide had GLP-2 receptor selectivity comparable to native hGLP-2.

    Peptide
    Apraglutide
    Outcome
    No significant changeGLP-2 receptor selectivity
    Study

    n: not reported in source

    GLP-2 receptor assay
    Comparator
    native hGLP-2
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective.
  13. 13LabIn vitro (cell-free)Pharmacokinetics

    In pharmacological studies, apraglutide had higher plasma protein binding than teduglutide and glepaglutide.

    In plain wordsIn lab tests, apraglutide bound blood proteins more strongly than teduglutide and glepaglutide.

    Peptide
    Apraglutide
    Outcome
    IncreasePlasma protein binding
    Study

    n: not reported in source

    Comparator
    teduglutide and glepaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pharmacokinetic (PK) and pharmacodynamic studies confirm that apraglutide, a novel GLP-2 analog, has very low clearance, long elimination half-life, and high plasma protein binding compared with GLP-2 analogs teduglutide and glepaglutide.
  14. 14LabOther designActivity measurement

    In laboratory receptor assays, teduglutide retained potency at GLP-2 receptors comparable to native hGLP-2.

    In plain wordsIn lab tests, teduglutide had GLP-2 receptor potency comparable to native hGLP-2.

    Peptide
    Teduglutide
    Outcome
    No significant changeGLP-2 receptor potency
    Study

    n: not reported in source

    GLP-2 receptor assays
    Comparator
    Native hGLP-2
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective.
  15. 15LabOther designActivity measurement

    In laboratory receptor assays, teduglutide retained GLP-2 receptor selectivity comparable to native hGLP-2.

    In plain wordsIn lab tests, teduglutide had GLP-2 receptor selectivity comparable to native hGLP-2.

    Peptide
    Teduglutide
    Outcome
    No significant changeGLP-2 receptor selectivity
    Study

    n: not reported in source

    GLP-2 receptor assays
    Comparator
    Native hGLP-2
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Versions 2 to 3

    27 Oct 2026, 16:37 UTC

    The same notice was added 2 times, first on 27 Oct 2026, 16:32 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.